FDA authorizes Blincyto® (blinatumomab) for CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) during consolidation stage.
Aimovig™ (erenumab) is an injectable human monoclonal antibody (mAb) co-developed and co-marketed by Novartis and Amgen, indicated for the preventive treatment of migraines in adults.
The researchers conducted a prospective docking of extensive compound libraries against the unoptimized AlphaFold2 (AF2) models of the σ2 receptor and the 5-HT2A receptor.
Jun 18th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Zura Bio Limited has recently unveiled positive results from a Phase 1 trial of its leading drug candidate, tibulizumab (ZB-106), aimed at treating Sjogren’s syndrome.
Genentech's Phase III STARGLO Trial Shows Columvi Significantly Prolongs Survival in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma.